To analyze the distribution and antibiotic resistance of multidrug-resistant organisms (MDROS) isolated in Anhui Chest Hospital in 2016.

A retrospective analysis was performed of the distribution and drug sensitivity of 165 clinical isolates of MDROS in Anhui Chest Hospital in 2016.

MDROS mainly included extended-spectrum beta-lactamase (ESBL) producing Escherichia coli, ESBL producing Klebsiella pneumoniae, carbopenem resistant Acinetobacter baumannii (CR-AB), methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), and multidrug resistant/pandrug resistant Pseudomonas aeruginosa (MDRPA). Specimens from which MDROS were isolated mainly included sputum, lavage fluid, and urine. Multidrug resistant Acinetobacter baumannii had the lowest resistance rate to amikacin (57%). ESBL producing Escherichia coli had the lowest resistance rates to imipenem and meropenem (0% for both). The sensitivity rates of ESBLs producing Klebsiella pneumoniae to imipenem and meropenem were both 86.8%. MDRPA had the lowest resistance rates to gentamicin and amikacin (11.6% and 17.3%, respectively). The sensitivity rates of MRSA and MRCNS to vancomycin and linezolid were both 100%.

The drug resistance of multidrug resistant bacteria is serious. Imipenem or meropenem has good antibacterial activity against ESBL producing Klebsiella pneumoniae and Escherichia coli, although carbapenem resistant Enterobacteriaceae strains have been detected. Amikacin and gentamicin have good antibacterial activity against CR-AB and MDRPA. Vancomycin and linezolid have the strongest antibacterial activity against MRSA and MRCNS.